...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Antibody persistence and booster response 68?months after vaccination at 2–10?years of age with one dose of MenACWY-TT conjugate vaccine
【24h】

Antibody persistence and booster response 68?months after vaccination at 2–10?years of age with one dose of MenACWY-TT conjugate vaccine

机译：抗体持久性和助推器响应68？疫苗接种后2-10岁以下，用一剂Menacwy-TT共轭疫苗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BackgroundWe evaluated antibody persistence up to 68?months (M) post-vaccination with a quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid conjugate vaccine (MenACWY-TT) or a licensed monovalent MenC conjugate vaccine (MenC-CRM197) and subsequent booster responses to MenACWY-TT in healthy European children.MethodsIn the initial study (NCT00674583), healthy children, 2–10?years of age, were randomized to receive a single dose of either MenACWY-TT or MenC-CRM197. In the follow-up study, we present the persistence at 32, 44, 56, and 68?M post-vaccination, overall and stratified by age (2–5 and 6–10?years), and the immunogenicity and safety of MenACWY-TT administered to all study participants at M68 post-primary vaccination.ResultsAt M68, 33.3% (age group 2–5?years) and 47.1% (age group 6–10?years) of the children vaccinated with MenACWY-TT, and 50.0% (age group 2–5?years) and 75.9% (age group 6–10?years) vaccinated with MenC-CRM197retained titers ≥1:8 for MenC, as assessed by a serum bactericidal assay using rabbit complement (rSBA). In the MenACWY-TT recipients, the percentages of children retaining rSBA titers ≥1:8 for MenA, MenW, and MenY were 81.7%, 47.3% and 66.7% in age group 2–5?years and 91.8%, 58,8% and 76.5% in age group 6–10?years, respectively. The booster dose induced robust responses (100% for all serogroups) and was well-tolerated.ConclusionsAntibody persistence (rSBA titers?≥?1:8) for serogroups A, W and Y was observed in more than 50.0% of the children 68?M after receiving one dose of MenACWY-TT; for MenC, antibody persistence was observed in more than one third of MenACWY-TT and more than half of MenC-CRM197recipients. Vaccination with a booster dose of MenACWY-TT induced robust immune responses for all serogroups.
机译：BackgroundWe评估抗体持久性高达68？月（m）与四肢脑膜炎球菌血清群A，C，W和Y Tetanus毒素结合疫苗（Menacwy-TT）或许可的单价Menc缀合物疫苗（Menc-CRM197）和随后的疫苗接种疫苗助推器对健康欧洲儿童梅纳韦-TT的反应。初步研究（NCT00674583），健康的儿童，2-10岁，随机接受单一剂量的Menacwy-TT或Menc-CRM197。在后续的研究中，我们提出在32的持久性，44，56，和68？m后接种疫苗，总体和按年龄（2-5和6-10？年）分层，和MenACWY的免疫原性和安全性-TT给M68后初级疫苗接种后的所有研究参与者。患有Menacwy-TT的儿童的儿童和47.1％（年龄组第6-10岁）和47.1％（年龄组第6-10岁）和47.1％（年龄组第6-10岁）。 50.0％（年龄组2-5？岁）和75.9％（6-10岁）与Menc-CRM197的滴度接种≥1：8，通过使用兔补蛋白（RSBA）的血清杀菌测定评估。在MENACWY-TT受者中，饲养RSBA滴度≥1：8的儿童的百分比为2-5岁的月桂，男性和MENY，47.3％和66.7％，47.3％和66.7％。年份和91.8％，58,8％年龄组6-10岁76.5％分别为76.5％。增强剂剂量诱导稳健的反应（所有血清群100％），并且耐受良好的血液持久性（RSBA滴度？≥β1：8）用于血清群A，在50.0％的儿童68以上观察到W和Y？ m收到一剂MENACWY-TT后;对于MENC，在Menacwy-TT中的三分之一以上和Menc-CRM197 recipients的一半以上，观察到抗体持久性。接种疫苗接种剂量的Menacwy-TT诱导所有血清小组的鲁棒免疫应答。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号